Andere Sprachen LianBio

Aktien

Verzögert OTC Markets Andere Börsenplätze 15:50:34 26.04.2024			% 5 Tage	% 1. Jan.
0,3097 ^USD	+3,93 %		+6,79 %	-93,07 %

13.02.	LianBio gibt Abschluss der strategischen Überprüfung bekannt	CI
2023	Nanobiotix-Partner überträgt asiatische Vermarktungsrechte für Onkologie-Therapie an Johnson & Johnson-Einheit	MT

LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index	18.03.
ADRs End Lower; Akso Health Group Declines 23%	15.03.
LianBio Announces Voluntarily Delisting from Nasdaq	28.02.
LianBio to Start Winding Down Operations; Complete Dissolution Expected in 2027	13.02.
LianBio Announces Completion of Strategic Review	13.02.
LianBio Announces Completion of Strategic Review	13.02.
Nanobiotix : transfert de droits sur NBTXR3 en Asie	27.12.
Nanobiotix Partner Transfers Asian Commercialization Rights for Oncology Therapy to Johnson & Johnson Unit	27.12.
Sector Update: Health Care Stocks Mixed Premarket Tuesday	26.12.
LianBio Assigns Rights to Nanobiotix's Oncology Therapy in China, Other Asian Markets to Janssen Pharmaceutica	26.12.
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets	26.12.
LianBio Enters into Agreement with Janssen Pharmaceutica to Assign its Rights for NBTXR3 in China and Other Asian Markets	26.12.
LianBio Finance Chief Resigns, Names Interim CFO	20.12.
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading	20.12.
LianBio Announces Departure of Chief Financial Officer	20.12.
LianBio Announces Chief Financial Officer Changes	20.12.
LianBio CEO Yizhe Wang Resigns; Board Member Adam Stone Named in Interim	19.12.
Lianbio Announces Resignation of Yizhe Wang as Member of the Board of Directors	19.12.
LianBio Announces Departure of Chief Executive Officer	19.12.
Lianbio Announces Chief Executive Officer Changes	19.12.

Keine Ergebnisse zu dieser Suche